Scientific Publication Update: Cancer Immunology
Irvine, CA, July 27, 2020 – On May 25, 2020, an article, “Antitumor efficacy of BAFF‑R targeting CAR T cells manufactured under clinic‑ready conditions”, has been published at Cancer Immunology, Immunotherapy.
To find the article on the web: https://link.springer.com/article/10.1007/s00262-020-02614-8
About PeproMene Bio
PeproMene Bio, Inc. is a virtual, privately funded biotech company located Irvine, CA. We are developing novel immune-oncology therapies such as BAFF-R CAR-T therapy based on the novel antibodies. The BAFF-R CAR-T therapy program which was discovered and developed from Dr. Larry Kwak’s lab at MD Anderson and City of Hope was successfully licensed in from City of Hope, Duarte CA, in April 2017. Currently the further development is ongoing at City of Hope for its IND enabling study. We will continue to license-in and explore more of novel immuno-oncology programs via our network. For more information about the Company, please visit www.pepromenebio.com.
Steve Lee: 949-564-4085, firstname.lastname@example.org